News & numbers What sponsors want


A new report from Florence Healthcare drew upon insights from 131 sponsors (CROs and sponsors were combined under the title of sponsor) to gauge the most important attributes they look for in a clinical trial site. It looked at how sponsors’ investment priorities have changed over recent years, with the deployment of technologies like electronic investigator site files (eISFs) increasing dramatically since 2021.


Rank the following study site attributes in order from most to least important


100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0%


Is accepting of sponsor or CRO-provided software such as eRegulatory or eConsent solutions


Utilises technology to provide remote monitoring access to our monitors/CRAs


Site staff is trained to use eRegulatory software


Sponsor investment in eISF Does your organisation deploy eISF's to study sites?


2021 2022 2023 11% 11% 54% 63% 27% 15% 78% 19% 22% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Sponsor investment in eSource Does your organisation deploy study eSource to study sites? 2021 2022 2023 21% 6% 54% 45% 23% 27% 73% 23% 28% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2021 2022 2023 47%


Utilises technology for electronic document and information exchange with


remote monitors/CRAs Is able to support


remote source workflows with source capture technology and remote monitors/CRAs


Communicates through purpose- built eClinical


technology consistently


Sponsor investment in eConsent Does your organisation deploy eConsent to study sites?


27% 9% 58% 25% 23% 64% 19% 28% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%


Sponsor investment in study start up tech Does your organisation deploy study start up tech to study sites?


2021 2022 2023 60% 24% 15% 73% 10% 18% 61% 17% 22% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% We do this We plan to invest We do not plan to invest Source: 2023 State of Clinical Trial Site Enablement Technology Report – Florence Healthcare Clinical Trials Insight / www.worldpharmaceuticals.net 7


1 2 3 4 5 6


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45